Volume 8 - Pre-proof (Accepted manuscript)
pbp 2026, 8 - Pre-proof (Accepted manuscript): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
kheiry M, Kaffashian M R, Aliboroni A, maleki M. Nanoparticle-Based Drug Delivery in Renal Ischemia-Reperfusion Injury: Insights into Molecular Signaling Pathways (Systematic review). pbp 2026; 8
URL: http://pbp.medilam.ac.ir/article-1-384-en.html
URL: http://pbp.medilam.ac.ir/article-1-384-en.html
1- Non-Communicable Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran
2- Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
3- Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran ,maryammaleki777@yahoo.com
2- Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
3- Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran ,
Abstract: (4 Views)
Objective: Renal ischemia-reperfusion injury (RIRI) is a major cause of acute kidney damage following surgery, trauma, organ transplantation, and thrombotic events, primarily due to oxidative stress and cellular injury. Nanoparticles (NPs) have emerged as promising therapeutic tools by enabling targeted drug delivery, controlled release, and reduced systemic toxicity. This systematic review evaluates the effects of NP-based therapies on IRIR, with a focus on their modulation of key molecular signaling pathways.
Methods: A systematic search was performed in PubMed, Scopus, and Web of Science for studies published between 1990 and 2024. After applying predefined inclusion and exclusion criteria, 14 studies were included in the final analysis.
Results: NP-based interventions consistently improved experimental RIRI outcomes by reducing oxidative stress, preserving renal function markers, attenuating inflammation and fibrosis, and modulating immune and gene-expression responses. These effects were observed across different nanoformulations and therapeutic cargos.
Conclusion: Current evidence supports nanoparticles as promising candidates for the prevention and treatment of renal IRIR, with clear potential for translation into advanced renal drug-delivery and renoprotective strategies.
Type of Study: Review/Systemtic review |
Subject:
Bioactive Compounds
Received: 2026/01/31 | Accepted: 2026/05/19 | Published: 2026/01/1
Received: 2026/01/31 | Accepted: 2026/05/19 | Published: 2026/01/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |